Actively Recruiting
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
Led by AstraZeneca · Updated on 2026-05-13
200
Participants Needed
7
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers. Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records. Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible. A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.
CONDITIONS
Official Title
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Advanced (unresectable or metastatic) non-small cell lung carcinoma
- Starting first-line oncological treatment in a participating center between January 2025 and January 2026
- Over 18 years old
- Data available in electronic medical records
You will not qualify if you...
- Localized disease amenable to local treatment
- Non-epithelial histology
- Small cell carcinoma
- Neuroendocrine tumor
- Patients with unresectable NSCLC treated with the PACIFIC protocol and currently followed up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Research Site
Recife, Brazil
Active, Not Recruiting
2
Research Site
Rio de Janeiro, Brazil
Actively Recruiting
3
Research Site
Rio de Janeiro, Brazil
Not Yet Recruiting
4
Research Site
Salvador, Brazil
Actively Recruiting
5
Research Site
Salvador, Brazil
Not Yet Recruiting
6
Research Site
São Paulo, Brazil
Active, Not Recruiting
7
Research Site
São Paulo, Brazil
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here